Heparin Gilvasan (Heparin Sodium)

Heparin Gilvasan is used in clinical settings where fast‑acting anticoagulation is required. It is indicated for several thrombotic and cardiovascular conditions.

• Prevention of venous thromboembolism in surgical or immobilized patients.
• Treatment of acute coronary syndromes, including unstable angina and myocardial infarction.
• Management of thrombotic disorders that need rapid anticoagulation, such as pulmonary embolism.
• Peri‑operative anticoagulation during cardiac or vascular surgery.
• Bridging therapy when transitioning between oral anticoagulants.

Heparin Gilvasan may cause a range of adverse reactions, from mild to severe. Understanding the typical and serious events helps clinicians monitor patients effectively.

Common

• Minor bleeding at catheter or injection sites.
• Small bruising or hematoma formation.
• Mild thrombocytopenia (platelet count decrease).
• Transient elevation of liver enzymes.
• Localized pain or irritation at the infusion site.

Serious

• Major hemorrhage, including gastrointestinal or intracranial bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Spinal or epidural hematoma when used near the central nervous system.

Before initiating Heparin Gilvasan, clinicians should assess patient‑specific factors and monitor therapy closely.

• Verify baseline coagulation parameters (aPTT, PT/INR) and platelet count.
• Adjust dose in patients with renal or hepatic impairment.
• Use caution in individuals with a history of heparin‑induced thrombocytopenia.
• Avoid concurrent use with other anticoagulants or antiplatelet agents unless medically justified.
• Monitor for signs of bleeding, especially in the gastrointestinal or central nervous systems.
• Counsel pregnant patients that safety data are limited; consider risk‑benefit ratio.
• Ensure proper intravenous technique to reduce local complications.

Heparin Gilvasan can interact with several medications, altering its anticoagulant effect or increasing bleeding risk.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring.
• Combination with antiplatelet drugs such as aspirin, clopidogrel, or NSAIDs.
• Administration alongside thrombolytic agents (e.g., alteplase, streptokinase).

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding.
• Certain antibiotics (e.g., ceftriaxone) that can affect platelet function.
• Glycoprotein IIb/IIIa inhibitors used in cardiac procedures.
• High‑dose corticosteroids that may exacerbate gastrointestinal bleeding.